Protalix BioTherapeutics (PLX) Cash & Equivalents (2010 - 2026)

Protalix BioTherapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $711000.0 for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 96.35% year-over-year to $711000.0 in Q1 2026; TTM through Mar 2026 was $711000.0, a 96.35% decrease from a year earlier, with the FY2025 full-year figure at $702000.0, down 96.45% from the prior year.
• Cash & Equivalents grew to $711000.0 in Q1 2026 per PLX's latest filing, from $702000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $48.2 million in Q2 2023 and bottomed at $702000.0 in Q4 2025.
• The 5-year median for Cash & Equivalents is $19.5 million (2025), against an average of $19.6 million.
• Across the five-year window, Cash & Equivalents surged 285.72% in 2023 and sank 96.45% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $17.1 million in 2022, then jumped by 38.12% to $23.6 million in 2023, then retreated by 16.39% to $19.8 million in 2024, then sank by 96.45% to $702000.0 in 2025, then gained by 1.28% to $711000.0 in 2026.
• Per Business Quant, the three latest PLX Cash & Equivalents figures stand at $711000.0 (Q1 2026), $702000.0 (Q4 2025), and $13.6 million (Q3 2025).